These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8225219)

  • 1. Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease.
    Tilg H; Vogel W; Wiedermann CJ; Shapiro L; Herold M; Judmaier G; Dinarello CA
    Hepatology; 1993 Nov; 18(5):1132-8. PubMed ID: 8225219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients.
    Rogy MA; Coyle SM; Oldenburg HS; Rock CS; Barie PS; Van Zee KJ; Smith CG; Moldawer LL; Lowry SF
    J Am Coll Surg; 1994 Feb; 178(2):132-8. PubMed ID: 8173722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
    Muzaffer MA; Dayer JM; Feldman BM; Pruzanski W; Roux-Lombard P; Schneider R; Laxer RM; Silverman ED
    J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis.
    Dinarello CA
    Kidney Int Suppl; 1992 Oct; 38():S68-77. PubMed ID: 1328757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist.
    Latini R; Bianchi M; Correale E; Dinarello CA; Fantuzzi G; Fresco C; Maggioni AP; Mengozzi M; Romano S; Shapiro L
    J Cardiovasc Pharmacol; 1994 Jan; 23(1):1-6. PubMed ID: 7511719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders.
    Libra M; Mangano K; Anzaldi M; Quattrocchi C; Donia M; di Marco R; Signorelli S; Scalia G; Zignego AL; de Re V; Mazzarino MC; Nicoletti F
    Oncol Rep; 2006 May; 15(5):1305-8. PubMed ID: 16596202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients.
    Khoruts A; Stahnke L; McClain CJ; Logan G; Allen JI
    Hepatology; 1991 Feb; 13(2):267-76. PubMed ID: 1995437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans.
    Bargetzi MJ; Lantz M; Smith CG; Torti FM; Olsson I; Eisenberg SP; Starnes HF
    Cancer Res; 1993 Sep; 53(17):4010-3. PubMed ID: 8395334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis.
    Naveau S; Abella A; Raynard B; Balian A; Giraud V; Montembault S; Mathurin P; Keros LG; Portier A; Capron F; Emilie D; Galanaud P; Chaput JC
    Am J Gastroenterol; 2001 Dec; 96(12):3361-7. PubMed ID: 11774950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis.
    Nagaki M; Iwai H; Naiki T; Ohnishi H; Muto Y; Moriwaki H
    J Infect Dis; 2000 Oct; 182(4):1103-8. PubMed ID: 10979906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice.
    Rosenbaum JT; Han YB; Park JM; Kennedy M; Planck SR
    J Rheumatol; 1998 Dec; 25(12):2408-16. PubMed ID: 9858438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of the usefulness of laparoscopic microwave coagulation therapy for hepatocellular carcinoma in patients with poor hepatic reserve by serial measurements of IL-6, cytokine antagonists, and C-reactive protein.
    Sadamori H; Yagi T; Kanaoka Y; Morimoto Y; Inagaki M; Ishikawa T; Matsukawa H; Matsuda H; Iwagaki H; Tanaka N
    Surg Endosc; 2003 Mar; 17(3):510-4. PubMed ID: 12399851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
    Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
    J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer.
    Barber MD; Fearon KC; Ross JA
    Clin Sci (Lond); 1999 Jan; 96(1):83-7. PubMed ID: 9857110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.